You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I (MP33)1 Sep 2021MP33-14 EFFICACY OF LOW INTENSITY ULTRASOUND-EXPOSED MAGNETOSOMES IN THE TREATMENT OF PROSTATE CANCER IN A XENOGRAFT MURINE MODEL Cynthia El Hedjaj, Eric Barret, Imene Chebbi, and Edouard Alphandery Cynthia El HedjajCynthia El Hedjaj More articles by this author , Eric BarretEric Barret More articles by this author , Imene ChebbiImene Chebbi More articles by this author , and Edouard AlphanderyEdouard Alphandery More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002042.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To ablate prostate tumors by intra-tumoral injection of magnetosomes and moderate ultrasound heating in a preclinical setting. METHODS: Nanoparticles used in this study were magnetosomes extracted and purified from magnetotactic bacteria. The resulting pure endotoxin free iron oxide minerals were coated with carboxy-methyl-dextran to yield stable coated magnetosome minerals (M-CMD). Treatment efficacy was tested on 4 groups of 10 mice each, bearing PC3-Luc tumours of ∼100 mm3. In vivo experiments followed the Charles Darwin ethical guidelines. Mice received intra-tumoral injection of isotonic solution (group 1), 3 µg per mm3 of tumour of M-CMD (group 2), the same injection of magnetosome as in group 2 followed by 10 sessions of 10 min (3 sessions per week), using a power of 1 W/cm2 and a frequency of 1 MHz (group 3), isotonic solution followed by the same sessions as in group 3 (group 4). Tumour growth after treatments was monitored by measurements of tumour volumes with a calliper and of tumour bioluminescence intensity (BLI). Histological analysis was carried out using Hematoxylin & Eosin/Pearl staining on tissues located in the region of the initial tumour following the various treatments. RESULTS: In group 3 mice, each session of ultrasound application led to an average tumour temperature of 45 °C during 8 minutes. The tumour volume decreased to 0 mm3, becoming un-palpable, and tumour BLI was undetectable 15 days following M-CMD administration. No tumour re-growth was observed during the 45 following days, suggesting full disappearance of the treated primary tumour. Histological analysis of collected tissues after the hyperthermia sessions revealed magnetosome cellular internalization, tumour cell apoptosis and necrosis, and an increase in the percentage of dead tumour cells with increasing number of hyperthermia sessions. In groups 1 and 2 not exposed to ultrasounds, tumours grew rapidly and mice had to be euthanized within one month following isotonic solution/M-CMD injection. In group 4 mice that had the same ultrasound sessions as in group 3 mice without M-CMD injection, a partial anti-tumour activity was observed. The treatment could not prevent tumour re-growth as in group 3. No major side effects were noted in the 4 groups. CONCLUSIONS: Intra-tumoral magnetosomes injection heated to a moderate temperature (45°) by low intensity ultrasounds is a safe and effective treatment of prostate cancer in a murine model. This technique appears promising for clinical applications since it is efficient on mice, relies on cheap and easy to use ultrasound device without a high level of focalisation. Source of Funding: Nanobacterie- 36 boulevard Flandrin, 75016 PARIS © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e612-e612 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Cynthia El Hedjaj More articles by this author Eric Barret More articles by this author Imene Chebbi More articles by this author Edouard Alphandery More articles by this author Expand All Advertisement Loading ...
Read full abstract